Market Access

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

A value deficit and potential consumer value proposition.

A new study found that among 2,200 patients with irritable bowel diseases, 63% encountered financial barriers that led to missed doses of medication.

Webinar Date/Time: Thu, Oct 17, 2024 11:00 AM EDT

The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.

As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.

The industry holds the key to true change to the drug access landscape.

A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.

The new vials of Zepbound are available through a new self-pay pharmacy channel, priced over 50% lower than other incretin medications for obesity.

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.

Key approval signals progress in addressing immune-mediated inflammatory diseases.

New cardiovascular indication builds on treatment’s fast-growing legacy.

Launch campaign ramped up for disease-modifying drug that targets rare and fatal form of hypertension.

How drugmakers can reap value from using generative AI in their market-entry strategies and decision-making, including mitigating launch challenges and enhancing the customer conversation.

The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.

One, tackle by price; the other, tackle with data.

A robust market access strategy ensures that pharmaceutical products, including those with limited distribution, reach patients and are covered by diverse healthcare systems.

JAMA study aims to determine whether financial barriers impact access to mental health services.

JAMA study evaluates changes to out-of-pocket costs and utilization of type 2 diabetes medications once patients reach the age of 65 years.

What pharma needs to do to keep up with the rise in value-based care.

Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.

With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount.

Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.

Leverage priorities in preclinical business planning.

Webinar Date/Time: Tue, Apr 23, 2024 1:00 PM EDT

Starting June 1, Boehringer Ingelheim plans to cap inhaler products for respiratory diseases at $35 per month for eligible patients.

JAMA commentary suggests that issues such as high costs, access, and equity will stop patients from obtaining GLP-1 agonists to treat obesity.

New guidance suggests that CMS may be ramping up Sunshine Act auditing activities, potentially resulting in monetary liability for noncompliant reporting entities.